Mechanisms of Disease: inflammatory mediators and cancer prevention
Jason R Mann, Michael G Backlund and Raymond N DuBois*
Correspondence *Vanderbilt-Ingram Cancer Center, 691 Preston Research Building, 2300 Pierce Avenue, Nashville, TN 37232-6838, USA
Email raymond.dubois@vanderbilt.edu
Discovery of molecular pathways critical to carcinogenesis is revolutionizing the treatment and prevention of cancer. This review discusses recent advances in colorectal cancer chemoprevention and the development of novel anti-inflammatory agents that target signaling pathways important in tumor formation and metastasis, such as those involving cyclooxygenase (COX1 and COX2) and the epidermal growth factor receptor (EGFR).
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Combinations for cancer preventionNature Medicine News and Views (01 Sep 2000)
COX-2 inhibitors for colorectal cancerNature Medicine News and Views (01 Apr 1998)
See all 3 matches for News And ViewsRESEARCH
Determination of an optimal dosing regimen for aspirin chemoprevention of 1,2-dimethylhydrazine-induced colon tumours in ratsBritish Journal of Cancer Scientific Correspondence
See all 20 matches for Research